# Development and validation of a clinical prediction model for first fall in early Parkinson’s disease: a study of two fall-naive cohorts

**Authors:** Yu Wang, Jianing Mei, Yunzhe Tang, Hongping Zhao, Zijun Wei, Qingliang Tao, Xueyi Han, Jiyuan Hu, Yunyun Zhang

PMC · DOI: 10.3389/fnagi.2026.1735524 · Frontiers in Aging Neuroscience · 2026-02-17

## TL;DR

Researchers developed a model to predict first falls in early Parkinson’s disease patients who haven’t fallen before, using five clinical factors.

## Contribution

The study introduces a new clinical prediction model for first falls in early PD patients without prior fall history.

## Key findings

- The model uses five predictors: BMI, orthostatic hypotension, cognitive score, depression score, and gait disorder score.
- The model showed strong discrimination with a C-index of 0.844 in training and 0.825 in external validation.
- The model outperformed existing approaches in predicting falls over 36 months.

## Abstract

Falls are frequent and debilitating complications in Parkinson’s disease (PD), with a substantial risk present even in early stages. Predicting the first fall is critical for preventive interventions, yet existing models are often unsuitable for fall-naive, early PD patients due to their reliance on fall history.

This study aimed to develop and externally validate a clinical prediction model for first falls in a population of fall-naive, early PD patients.

This prognostic model study used data from two cohorts: the Parkinson’s Progression Markers Initiative (PPMI) for model development (n = 283) and internal validation (n = 120), and an independent Chinese cohort for external validation (n = 150). Participants were fall-naive with early PD (Hoehn and Yahr stage 1–2) and were followed for 36 months. The primary outcome was time to the first fall. A Cox proportional hazards model was developed using readily accessible clinical variables. Model performance was assessed using discrimination (C-index, AUC), calibration, and decision curve analysis.

During follow-up, 16.9% of PPMI participants and 20.7% of the Chinese cohort experienced a first fall. The final model incorporated five independent predictors: lower body mass index, asymptomatic orthostatic hypotension, lower Montreal Cognitive Assessment score, a Geriatric Depression Scale-15 score > 5, and a higher postural instability and gait disorder score. The model demonstrated good discrimination with an optimism-corrected C-index of 0.844 in the training set and maintained its performance in both internal (C-index: 0.768) and external validation (C-index: 0.825). Decision curve analysis indicated that the model demonstrated superior clinical net benefit for predicting falls over 36 months compared to 18 months.

A history of falls is not necessary to predict the first fall in early PD. Our externally validated model, based on five easily ascertainable clinical factors, provides a practical tool for early risk stratification and can help guide individualized preventive strategies to delay or prevent initial falls in this vulnerable population.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** Movement Disorder (MESH:D009069), cognitive decline (MESH:D003072), axial dysfunctions (MESH:C537791), REM Sleep Behavior Disorder (MESH:D020187), hydrocephalus (MESH:D006849), rigidity (MESH:D009127), progressive supranuclear palsy (MESH:D013494), myopathy (MESH:D009135), peripheral neuropathy (MESH:D010523), dysfunction (MESH:D006331), parkinsonism (MESH:D010302), dementia (MESH:D003704), Depression (MESH:D003866), freezing of gait (MESH:D020234), H&amp;Y (MESH:C536297), dizziness (MESH:D004244), hyposmia (MESH:D000086582), DDS (MESH:D030321), OH (MESH:D007024), psychosis (MESH:D011618), deaths (MESH:D003643), malnutrition (MESH:D044342), blood (MESH:D006402), TD (MESH:D014202), bradykinesia (MESH:D018476), PIGD (MESH:D054972), Hallucinations and (MESH:D006212), autonomic dysfunction (MESH:D001342), frailty (MESH:D000073496), drop (MESH:D020427), multiple system atrophy (MESH:D019578), fatigue (MESH:D005221), vertigo (MESH:D014717), stroke (MESH:D020521), gait dysfunction (MESH:D020233), Falls (MESH:C537863), traumatic brain injuries (MESH:D000070642), Anxiety (MESH:D001007), Alzheimer's disease (MESH:D000544), psychiatric disorders (MESH:D001523), tumor (MESH:D009369), visual impairment (MESH:D014786), Sleep-wake dysfunction (MESH:D012893), fractures (MESH:D050723), PD (MESH:D010300), sarcopenia (MESH:D055948), neurodegenerative disorder (MESH:D019636), injuries (MESH:D014947), dopamine dysregulation syndrome (MESH:C567730), sympathetic denervation (MESH:D006732)
- **Chemicals:** dopamine (MESH:D004298), levodopa (MESH:D007980)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953559/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953559/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953559/full.md

---
Source: https://tomesphere.com/paper/PMC12953559